1-8 of 8
Jesse Boumelha
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT106: A phase 1b/2 trial of dupilumab given in conjunction with PD-1 or PD-L1 blockade and anakinra in the treatment of relapsed/refractory metastatic NSCLC

Jacob A. Lowy, Matthew D. Park, Nicholas C. Rohs, Pamela Vaiskauskas, Fionnuala Crowley, Nicholas Venturini, Stephanie Chang, Nelson LaMarche, Clotilde Hennequin, Jessica Le Berichel, Pauline Hamon, Meriem Belabed, Nader Yatim, Jesse Boumelha, Alexis Saffon, Frederika Rentzeperis, Brian Y. Soong, Leanna Troncoso, Laszlo Halasz, Christina Noel, Theodore Chin, Earnest P. Chen, Amanda Reid, Maria Casanova-Acebes, Matthew Su, Ashley Reid, Shira Wood-Isenberg, Darwin D’souza, Travis Dawson, Kai Nie, Zhihong Chen, Jorge E. Gomez, Seunghee Kim-Schulze, Filip K. Swirski, Nicolas Vabret, Udit Chaddha, Dan Feng, Mary B. Beasley, David F. Yankelevitz, Deborah B. Doroshow, Rajwanth Veluswamy, Robert Samstein, Brian D. Brown, Fred R. Hirsch, Sacha Gnjatic, Miriam Merad, Thomas U. Marron
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT106.
https://doi.org/10.1158/1538-7445.AM2025-CT106
Published: 25 April 2025
View articletitled, Abstract CT106: A phase 1b/2 trial of dupilumab given in conjunction with PD-1 or PD-L1 blockade and anakinra in the treatment of relapsed/refractory metastatic NSCLC
Journal Articles

CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer

Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Phil East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
Journal: Cancer Research
Cancer Res (2024) 84 (14): 2231–2246.
https://doi.org/10.1158/0008-5472.CAN-23-2627
Published: 15 July 2024
View articletitled, CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Open the PDF for CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 5733: Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer

Panayiotis Anastasiou, Mona Tomaschko, Jesse Boumelha, Sareena Rana, Christopher Moore, Miriam Molina-Arcas, Julian Downward
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5733.
https://doi.org/10.1158/1538-7445.AM2023-5733
Published: 04 April 2023
View articletitled, Abstract 5733: Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Journal Articles

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations

Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, Pablo Romero-Clavijo, Matthew A. Coelho, Kevin W. Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R. Caswell, Miguel Murillo, David C. Hancock, Prokopios P. Argyris, William L. Brown, Cameron Durfee, Lindsay K. Larson, Rachel I. Vogel, Alejandro Suárez-Bonnet, Simon L. Priestnall, Philip East, Sarah J. Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Harris, Julian Downward
Journal: Cancer Research
Cancer Res (2022) 82 (19): 3435–3448.
https://doi.org/10.1158/0008-5472.CAN-22-0325
Published: 04 October 2022
View articletitled, An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
Open the PDF for An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations in another window
Includes: Supplementary data
Journal Articles

Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Jesse Boumelha, Pablo Romero-Clavijo, Sophie de Carné, Miriam Molina-Arcas, Julian Downward
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1352.
https://doi.org/10.1158/1538-7445.AM2022-1352
Published: 15 June 2022
View articletitled, Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer
Journal Articles

Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Panayiotis Anastasiou, Edurne Mugarza, Jesse Boumelha, Sareena Rana, Christopher Moore, Miriam Molina-Arcas, Julian Downward
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4029.
https://doi.org/10.1158/1538-7445.AM2022-4029
Published: 15 June 2022
View articletitled, Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity
Journal Articles

Abstract 1390: Immunotherapy boosts B cell responses in lung adenocarcinoma

Katey Enfield, Kevin Ng, Jesse Boumelha, Kevin Litchfield, Oriol Pich, TRACERx Consortium, Charles Swanton, George Kassiotis, Julian Downward
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1390.
https://doi.org/10.1158/1538-7445.AM2022-1390
Published: 15 June 2022
View articletitled, Abstract 1390: Immunotherapy boosts B cell responses in lung adenocarcinoma
Journal Articles

Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer

Jesse Boumelha, Sophie de Carné, Edurne Mugarza, Pablo Romero-Clavijo, Miriam Molina-Arcas, Julian Downward
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1820.
https://doi.org/10.1158/1538-7445.AM2021-1820
Published: 01 July 2021
View articletitled, Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer